Abingdon Health has signed a non-exclusive sales and distribution agreement with BioSure UK to distribute its AbC-19 rapid neutralising antibody test for Covid-19 across the UK and Europe.
The parties intend to establish a strategic distribution relationship to identify and maximise opportunities for the sale of the test across the UK and the continent.
Healthcare, workplace and pharmacy settings will be prioritised as antibody test results become more relevant following the vaccination rollout.
AbC-19 is a single-use test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus in whole blood.
The antibodies can be detected from a finger-prick of blood in 20 minutes, and can indicate whether a person has produced an immune response following Covid-19 infection or vaccination.
Abingdon CEO Chris Yates said: “Where antibody tests were once predominantly used for charting the spread of infection within communities, today they emerging as a key pillar of large-scale immunisation campaigns.
“Rapid antibody tests such as AbC-19 that target the full trimeric spike can help policymakers and healthcare networks further understand immunity to Covid-19 and the effectiveness of vaccine programmes.”
Antibody testing has the potential to inform vaccination programmes and health policy by showing how Covid-19 infection has spread through communities, where and why immunity might be developing and how mass-immunisation campaigns should be designed.
Abingdon is the organisation behind the UK Rapid Test Consortium (UK-RTC), which it founded in response to a UK Government call for businesses to work together on a rapid antibody test to be rolled out nationally.
The consortium’s members also include BBI Solutions, CIGA Healthcare and Omega Diagnostics. While antibodies undoubtedly have a role to play in Covid-19 immunity, researchers believe T-cells could also have a significant impact.